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APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor
suppressor axis
Erik S. Blomain*, Jeffrey A. Rappaport*, Amanda M. Pattison*, Babar Bashir
Adam E. Snook , and Scott A. Waldman

*, Ellen Caparosa, Jonathan Stem,

Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA
ABSTRACT

Sporadic colorectal cancer initiates with mutations in APC or its degradation target β-catenin, producing
TCF-dependent nuclear transcription driving tumorigenesis. The intestinal epithelial receptor, GUCY2C,
with its canonical paracrine hormone guanylin, regulates homeostatic signaling along the crypt-surface
axis opposing tumorigenesis. Here, we reveal that expression of the guanylin hormone, but not the
GUCY2C receptor, is lost at the earliest stages of transformation in APC-dependent tumors in humans
and mice. Hormone loss, which silences GUCY2C signaling, reflects transcriptional repression mediated
by mutant APC-β-catenin-TCF programs in the nucleus. These studies support a pathophysiological
model of intestinal tumorigenesis in which mutant APC-β-catenin-TCF transcriptional regulation eliminates guanylin expression at tumor initiation, silencing GUCY2C signaling which, in turn, dysregulates
intestinal homeostatic mechanisms contributing to tumor progression. They expand the mechanistic
paradigm for colorectal cancer from a disease of irreversible mutations in APC and β-catenin to one of
guanylin hormone loss whose replacement, and reconstitution of GUCY2C signaling, could prevent
tumorigenesis

Introduction
There is a well-established relationship between mutations in
the APC tumor suppressor and colorectal cancer,1−5 the 4th
most common cancer, and the 2nd leading cause of cancer
death.6 The current paradigm suggests that monoallelic inactivation creates APC heterozygosity and a potential vulnerability for tumorigenesis.1-5,7 This potential is realized by
a second event resulting in functional loss of heterozygosity
(LOH), eliminating APC from a destruction complex which
targets β-catenin for ubiquitination and proteasomal
degradation.1-5,7 As a consequence, cytosolic β-catenin accumulates and translocates to the nucleus, and with its binding
partner TCF, re-programs transcription to drive
transformation.8-11 Indeed, ≥90% of sporadic colorectal cancers initiate with inactivating mutations in APC (~85%) or
mutations in β-catenin that block degradation (~5%).1-5
However, specific molecular mechanisms coupling these
mutations to tumorigenesis continue to be refined.
GUCY2C is the membrane-bound receptor guanylate cyclase
expressed by intestinal epithelial cells.12,13 Canonical GUCY2C
ligands include uroguanylin produced in small intestine, guanylin produced in colorectum, and bacterial heat-stable enterotoxins (STs), all of which increase epithelial cell cyclic guanosine
monophosate (cGMP).12,13 The GUCY2C-cGMP signaling axis
modulates intestinal secretion, one mechanism by which bacteria induce diarrhea.14-16 Linaclotide (Linzess™) and plecanatide
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(Trulance™) are orally available GUCY2C ligands that are congeners of ST and uroguanylin, respectively. These peptides
increase intestinal secretion and are FDA-approved to treat
chronic constipation syndromes.13,17
The architecture of the intestinal epithelium is maintained
by continuous regenerative cycles of proliferation, migration,
differentiation, and apoptosis.18-23 In turn, these are the processes that are canonically disrupted in cancer.24 Beyond
secretion, the paracrine hormone-GUCY2C signaling axis
regulates these normal homeostatic processes.18-23 In that
context, silencing GUCY2C produces crypt hyperplasia,
increasing proliferating progenitor cells and accelerating
their cell cycle.18,19,21-23 Conversely, GUCY2C signaling inhibits proliferation by decreasing β-catenin and its transcriptional targets cyclin D and Myc.18,19,21,22 Also, there is
a metabolic gradient along the crypt-surface axis, where proliferating crypt cells depend on glycolysis, while differentiated
surface cells depend on oxidative phosphorylation.19 Silencing
GUCY2C imposes an aberrant phenotype along that axis,
characterized by reduced mitochondria, increased glycolysis,
and decreased oxygen consumption, recapitulating the
Warburg metabolic phenotype in tumors.19 Moreover, silencing GUCY2C increases DNA oxidation and double strand
breaks, mutagenesis induced by alkylating agents, and chromosomal instability18,19
Guanylin is reduced,25-28 while GUCY2C is conserved,29-31
in colorectal adenomas and carcinomas in humans and mice.
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In that context, GUCY2C agonists reduce epithelial transformation in genetic, carcinogen, and inflammatory mouse models of intestinal tumorigenesis.26,32-35 These observations
suggest a pathophysiological model in which transformation
reduces guanylin expression, driving tumorigenesis by suppressing GUCY2C-cGMP signaling. Here, we reveal that guanylin hormone expression is eliminated, and GUCY2C-cGMP
signaling is silenced, as an immediate downstream consequence of mutant APC-β-catenin-TCF nuclear transcriptional
re-programming.

Results
Guanylin hormone, but not the GUCY2C receptor, is lost
in human colorectal tumorigenesis
Guanylin protein (Figure 1a–c) and mRNA (Figure 1d) are
eliminated in human colorectal adenocarcinomas compared
to normal mucosa. Residual guanylin mRNA or protein in
some tumors reflects incomplete dissection of associated normal mucosa from pathology specimens. These results are
consistent with those obtained with samples from the
TCGA,36 which revealed a median reduction of ~250-fold in
GUCA2A mRNA in 339 tumors with mutations in the APCβ-catenin signaling pathway compared to 51 normal tissues
(Figure 1e). Loss of hormone expression is an early event in

transformation, and guanylin protein (Figure 1a–c) and
mRNA (Figure 1f) are absent in tubular adenomas, which
arise primarily from mutations in APC-β-catenin-TCF
signaling,1-5,7,40 compared to normal tissue in patients.
Similar results were obtained with tissues in a GEO dataset
(accession number GSE8671),37-39 which revealed a median
reduction of ~250-fold in GUCA2A mRNA in 32 adenomas
with mutations in the APC-β-catenin signaling pathway compared to matched normal adjacent tissues (Figure 1g).
Further, guanylin hormone expression is absent in tumors
from patients with familial adenomatous polyposis (FAP),
a hereditary colorectal cancer syndrome in which patients
are heterozygous for one mutant allele of APC (Figure 1a,b,
h; Supplementary Figure 1). Hormone loss associated with
reductions in mRNA in transformed tissue does not reflect
gene mutations or changes in chromosomal structure and
there were only 2 tumors with missense mutations in the
GUCA2A gene from a total of 1378 colorectal adenocarcinomas with mutations in APC or CTNNB1 (β-catenin) in the
cBioPortal database.41,42
In contrast to the hormone guanylin, expression of
GUCY2C protein and mRNA are maintained in adenocarcinomas (Figure 2a–d) and tubular adenomas (Figure 2a–e; see
Figure 1a for H&E micrographs). These results agree with
those obtained with samples from the TCGA,36 in which
expression of GUCY2C mRNA was preserved in 339 tumors

Figure 1. Loss of GUCA2A expression in tumors in human colorectum.
(a-c) GUCA2A protein quantified by (a-b) immunofluorescence or (c) immunoblot (a representative immunoblot is displayed) in adenocarcinomas (sporadic and FAP),
adenomas, and normal mucosa. Where appropriate, matched normal adjacent tissues (NAT) and tumors from the same patient are highlighted with a connecting
line. Corresponding H&E images (a) highlight histological changes associated with transformation. (d) GUCA2A mRNA quantified by RT-PCR in adenocarcinomas and
matched normal mucosa (n = 17). (e) GUCA2A mRNA expression quantified by RNASeq in adenocarcinomas (n = 339) and normal mucosa (n = 51) from human
colorectum from the TCGA database.36 (f) GUCA2A mRNA quantified by RT-PCR in tubular adenomas (9) and normal mucosa (n = 8). (g) GUCA2A mRNA expression
quantified by RNASeq in adenomas and matched normal mucosa (n = 32) from the human colorectum from a GEO dataset (accession number GSE8671).37-39 (h)
GUCA2A mRNA quantified by RT-PCR analysis in FAP adenomas (n = 5) and normal mucosa (n = 6). Green, GUCA2A; blue, DAPI. *, p < .05; **, p < .01; ***, p < .001,
****, p < .0001. Scale bar = 100 µm.
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with mutations in the APC-β-catenin signaling pathway, compared to 51 normal tissues (figure 2f). Similarly, they agree
with results obtained with samples from a GEO dataset
(accession number GSE8671),37-39 in which expression of
GUCY2C mRNA was preserved in 32 adenomas with mutations in the APC-β-catenin signaling pathway, compared to
matched normal adjacent tissues (Figure 2g). Further,
GUCY2C protein (Figure 2a,b) and mRNA (Figure 2h)
expression was maintained in adenomas from patients with
FAP (see Figure 1a for H&E micrographs). Moreover, the
GUCY2C gene is a “cold spot” and there were 14 tumors
with missense mutations in, and 1 tumor with a deletion of,
the GUCY2C gene from a total of 1378 colorectal adenocarcinomas with mutations in APC or CTNNB1 in the cBioPortal
database.41,42 Taken together, these observations reveal that
guanylin hormone mRNA and protein expression is lost, but
expression of the GUCY2C receptor is maintained, in the
earliest stages of APC-driven transformation in patients.

disrupt hormone expression. In that context, ApcCKO/CKO mice
in which biallelic Apc loss can be conditionally induced in
a temporal- and tissue-specific fashion, recapitulating the initiating event in intestinal tumorigenesis,1-5,7,40 provide a unique
opportunity to test this hypothesis. Tamoxifen-induced biallelic
loss of Apc in intestinal epithelial cells of vil-Cre-ERT2-ApcCKO/CKO
mice activated canonical Wnt signaling, with accumulation of βcatenin and its downstream transcriptional targets c-Myc and
Axin2 (Figure 3a,b). This dysregulated Wnt signaling disrupted
normal epithelia architecture, with attenuation of villus structures,
crypt hyperplasia, and extension of PCNA+ proliferating cells,
normally confined to the crypt base, along the crypt-surface axis
(Figure 3c). Biallelic Apc loss eliminated guanylin, but not
GUCY2C, protein and mRNA expression (Figure 3d–f). Loss of
guanylin hormone silenced the retained GUCY2C receptor
(Figure 3d,f), reducing phosphorylation of vasodilatorstimulated phosphoprotein (VASP), an immediate downstream
target of cGMP signaling in intestinal epithelial cells (Figure 3d)34

Mutations in APC drive the loss of guanylin, but not
GUCY2C, in mice

APC-β-catenin-TCF signaling suppresses guanylin
expression in human colorectal cancer cells

Loss of guanylin at the earliest stages of tumorigenesis in patients
supports a mechanism in which mutations in APC signaling

The foregoing suggests that oncogenic signaling produced by
mutations in APC that drive intestinal tumorigenesis silence

Figure 2. Retention of GUCY2C expression in tumors in human colorectum.
(a-c) GUCY2C protein quantified by (a-b) immunofluorescence or (c) immunoblot (canonical doublet at 140–160 kDa) in adenocarcinomas (sporadic and FAP) and
adenomas and normal mucosa. Where appropriate, matched normal adjacent tissues (NAT) and tumors from the same patient are highlighted with a connecting line.
(d) GUCY2C mRNA quantified by RT-PCR in adenocarcinomas and matched normal mucosa (n = 17). (e) GUCY2C mRNA quantified by RT-PCR analysis in tubular
adenomas (n = 8) and normal mucosa (n = 9). (f) GUCY2C mRNA expression quantified by RNASeq in carcinomas (n = 339) and normal mucosa (n = 51) from human
colorectum from the TCGA database.36 (g) GUCY2C mRNA expression quantified by RNASeq in adenomas and matched normal mucosa (n = 32) from the human
colorectum from a GEO dataset (accession number GSE8671).37-39 (h) GUCY2C mRNA quantified by RT-PCR analysis in FAP adenomas (n = 5) and normal mucosa
(n = 6). Red, GUCY2C; blue, DAPI. ns, not significant. Scale bar = 100 µm.
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Figure 3. GUCA2A and GUCY2C in colonocytes following biallelic Apc in-activation in mice.
Wildtype (WT) and vil-Cre-ERT2-ApcCKO/CKO (CKO) mice received 100 mg/kg tamoxifen IP and colons with crypts were harvested 5 days later. (a) Immunblot analysis of
APC, β-catenin and its downstream transcriptional targets. (b) Quantification of c-MYC and Axin2 mRNA by RT-PCR. (c) H&E and PCNA+ cell staining of colons from
WT and CKO mice. (d) Immunoblot analysis of GUCA2A, GUCY2C, and their downstream signaling target, phosphorylated (P-)VASP. (e) Quantification of GUCA2A and
GUCY2C mRNA by RT-PCR. (f) Immunofluorescence of GUCY2C (magenta), GUCA2A (green) and DAPI (blue) in colons from WT and CKO mice. ns, not significant; *,
p < .05; ****, p < .0001. Scale bar = 100 µm.

the expression of the hormone guanylin. Loss-of-function
mutations in APC, or gain-of-function mutations in βcatenin, produce accumulation and nuclear translocation of βcatenin, where it binds to the TCF4 transcription factor to reprogram gene expression driving transformation.8-11 In that
context, we directly tested the individual roles of APC, βcatenin, and TCF4 in the regulation of guanylin expression.
HT29 human colon cancer cells express mutant APC and are
devoid of guanylin mRNA and protein expression (Figure
4a).43 Induced expression of a wild type APC transgene in
these cells restores normal Wnt signaling (Figure 4b,
Supplementary Figure 2) and interrupts expression of βcatenin downstream transcriptional targets (Figure 4c).43
Further, restoring the expression of wild type APC reconstitutes the expression of guanylin mRNA (Figure 4d) and protein
(Figure 4e). Similarly, LS174T human colon cancer cells
express mutant β-catenin, and also are devoid of guanylin
mRNA and protein expression (Figure 4f).10,44 Induced suppression of mutant β-catenin expression with siRNA in these

cells (Figure 4g) interrupts the expression of its downstream
transcriptional targets (Figure 4h). Suppression of mutant βcatenin in these cells reestablishes the expression of guanylin
mRNA and protein (Figure 4i,j). Finally, DLD1 human colon
cancer cells express mutant APC and wild type β-catenin and
are devoid of guanylin mRNA and protein expression (Figure
4k).10,44 Induced expression of a dominant negative form of
TCF4 in these cells (Figure 4k,l) interrupts the expression of its
downstream transcriptional targets (Figure 4m). Moreover, the
dominant negative form of TCF4 restores the expression of
guanylin mRNA and protein in these cells (Figure 4n,o).
Dominant negative TCF similarly reconstituted guanylin
mRNA and protein expression in LS174T cells
(Supplementary Figure 3). Moreover, hormone expression is
temporally linked to alterations in APC-β-catenin signaling,
and guanylin mRNA recovers within hours of DNTCF protein
expression (Supplementary Figure 4). Taken together, these
observations demonstrate that guanylin mRNA and protein
expression is suppressed by APC-β-catenin-TCF signaling.
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Figure 4. Regulation of GUCA2A expression by APC-β-catenin-TCF signaling in human colon cancer cells.
(a-b) HT29 cells carrying a transgene containing wildtype APC under a zinc-inducible promoter43 and treated with 300 μM zinc express wild type APC, with an
associated loss of β-catenin, in a time-dependent fashion. (c) Induction of wildtype APC reduced (red) downstream transcriptional targets upregulated by β-cateninTCF signaling and increased (green) transcriptional targets downregulated by β-catenin-TCF signaling. (D-E) Wildtype APC induced expression of GUCA2A (d) mRNA
and (e) protein. (f-g) A transgene containing an siRNA to β-catenin under the control of a doxycycline-inducible promoter in LS174T cells10,44 suppressed the
accumulation of β-catenin when treated with 1 μg/mL doxycycline. (h) Suppression of β-catenin reduced (red) downstream transcriptional targets upregulated by βcatenin-TCF signaling and increased (green) transcriptional targets downregulated by β-catenin-TCF signaling. (i-j) Suppression of β-catenin induced expression of
GUCA2A (i) mRNA and (j) protein. (k-l) A transgene containing DNTCF under the control of a doxycycline-inducible promoter in DLD1 cells10,44 inhibited TCF activity
when treated with 1 μg/mL doxycycline. (m) Induction of DNTCF reduced (red) downstream transcriptional targets upregulated by β-catenin-TCF signaling and
increased (green) transcriptional targets downregulated by β-catenin-TCF signaling. (N-O) DNTCF induced expression of GUCA2A (n) mRNA and (o) protein. (c, h, m)
Gene expression normalized to non-induced cells and transformed to a log2 scale. *, p < .05; **, p < .01; ***, p < .001; ****, p < .0001.

APC-β-catenin-TCF signaling regulates guanylin nuclear
transcription
Loss of guanylin in adenomas and tumors is associated with
reduced expression of the mRNA for the hormone. Also, guanylin loss in epithelial cells following dysregulation of APC-βcatenin-TCF signaling is associated with loss of the transcript
for the hormone. Moreover, APC-β-catenin-TCF signaling,
which regulates guanylin expression, induces re-programming
of
nuclear
transcription
circuits
which
drives
transformation.8-11 Here, we explored the contribution of
nuclear transcription of new mRNA to the regulation of guanylin expression by APC-β-catenin-TCF signaling. Nascent
guanylin mRNA was labeled with ethynyl-uridine and biotinazide click-chemistry, followed by affinity purification and
quantification by qRT-PCR analysis (Figure 5a).45,46 In HT29
human colorectal cancer cells, induction of transgenic wild type
APC (Figure 5b-c) reconstitutes the generation of nascent

guanylin mRNA (Figure 5d). Similarly, in LS174T human colorectal cancer cells, suppression of mutant β-catenin with siRNA
(Figure 5e-f) restores guanylin mRNA synthesis (Figure 5g).
Finally, in DLD1 human colorectal cancer cells, induced expression of DNTCF (Figure 5h-i) reestablishes nascent guanylin
mRNA synthesis (Figure 5j). These observations demonstrate
that dysregulated APC-β-catenin-TCF signaling mediates guanylin hormone loss as part of its canonical re-programming of
nuclear transcription.8-11

Discussion
Mutations in APC that constitutively activate Wnt signaling
initiate more than 80% of sporadic, and 100% of FAPassociated, colorectal tumors.1-5,7,40 Mutations in APC typically result in loss of function, inactivating the multimeric
protein complex targeting β-catenin for proteasomal
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Figure 5. APC-β-catenin-TCF signaling suppresses the expression of new guanylin mRNA transcripts.
(a) Schematic shows EU-incorporation into newly synthesized RNA, biotinylation by click-chemistry, and isolation with magnetic streptavidin beads. (b-d) Treatment
with 300 μM zinc of HT29 cells carrying a transgene containing wild type APC under a zinc-inducible promoter43 induced the accumulation of nascent guanylin
mRNA transcripts labeled with EU. (e-g) Treatment with 1 μg/mL doxycycline of LS174T cells carrying a transgene containing an siRNA to β-catenin under the control
of a doxycycline-inducible promoter10,44 induced the accumulation of nascent guanylin mRNA transcripts labeled with EU. (h-i) Treatment with 1 μg/mL doxycycline
of DLD1 cells carrying a transgene containing DNTCF under the control of a doxycycline-inducible promoter10,44 induced the accumulation of nascent guanylin mRNA
transcripts labeled with EU. **, p < .01; ***, p < .001; ****, p < .0001.
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degradation.1,2,4,7,8 In turn, β-catenin accumulates in the cytosol, translocates to the nucleus and binds to TCF, reprogramming transcription that drives transformation.9,10
While a role for APC in intestinal tumorigenesis is well
established, mechanistic steps leading from dysregulated
Wnt signaling to transformation continue to be defined.
Here, we reveal that loss of the hormone guanylin, which
silences the GUCY2C receptor, is mediated by mutant APCβ-catenin signaling. In that context, guanylin loss, and
GUCY2C silencing, is universal in tubular adenomas and
adenocarcinomas initiated by mutations in APC signaling in
patients. It is one of the earliest events in tumorigenesis and is
tightly linked temporally with mutant APC-β-catenin signaling. Guanylin loss is highly conserved across species in which
APC mutations drive tumorigenesis, including mice and
humans. Moreover, loss-of-function mutations in APC, or
gain-of-function mutations in β-catenin, produce a TCFdependent block of nuclear guanylin mRNA transcription
that eliminates hormone production in mouse intestine
in vivo and in human colorectal cancer cells in vitro.
Together, these observations demonstrate that transcriptional
repression of guanylin hormone production which silences
the GUCY2C receptor is an immediate downstream consequence of dysregulated APC-β-catenin signaling that canonically drives intestinal transformation.
APC-β-catenin-TCF signaling regulates guanylin hormone
production by eliminating the expression of newly synthesized
transcripts. In that context, the precise mechanisms by which
APC-β-catenin-TCF signaling regulates guanylin transcription remain to be defined. While APC and β-catenin signal
through transcriptional regulation of gene expression,9,10
chromatin immunoprecipitation and mRNA sequencing
(ChIP-seq) analysis reveals that they do not bind directly to
the guanylin promoter in murine intestinal crypt cells and
human colorectal cancer cell lines in which guanylin expression is suppressed (Supplementary Figure 5). In that context,
guanylin expression in intestinal cells requires association of
the hepatocyte nuclear factor-1α (HNF-1α) transcription factor to a consensus nucleotide binding site located in the
immediate 5ʹ-flanking region of the promoter.47 However,
the expression of HNF-1α is not reduced in tumors nor
regulated by APC-β-catenin-TCF signaling (Supplementary
Figure 6).11 Beyond HNF-1α, transcription factors regulating
the expression of guanylin remain undefined. In silico mapping of the guanylin promoter (Encode: UCSC Genome
Browser database)48 reveals consensus binding sequences for
transcription factors, including those regulated by APC-βcatenin-TCF signaling. These observations are consistent
with a hypothesis, currently being explored, in which APC-βcatenin-TCF signaling regulates the expression of the guanylin
gene through its downstream canonical transcriptional regulatory network that drives oncogenesis.11
Early universal loss of guanylin, silencing GUCY2C, in
a mechanism conserved across species, suggests that the paracrine hormone-GUCY2C-cGMP axis opposes intestinal transformation induced by mutant APC-β-catenin signaling.
Indeed, silencing GUCY2C amplifies intestinal tumorigenesis
produced by mutations in Apc or by the carcinogen azoxymethane (AOM) in mice.18,19,34 Conversely, luminal
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replacement of GUCY2C agonists reduces the number and
size of tumors driven by Apc mutations in mice.26,32,33,35
These observations support the hypothesis that guanylin loss
and silencing of the GUCY2C axis is one molecular mechanism contributing to the progression of tumorigenesis initiated
by mutant APC-β-catenin-TCF signaling.
The precise mechanisms by which guanylin-GUCY2CcGMP signaling opposes intestinal tumorigenesis remain to
be defined. For example, GUCY2C signaling activates p53,
reduces DNA damage, and amplifies DNA damage repair
opposing spontaneous and carcinogen-induced mutational
events, which could block Apc LOH in cells heterozygous
for this tumor suppressor.18-20,49 Alternatively, GUCY2C
inhibition of cell cycle drivers, like cyclin D, and activation
of cell cycle inhibitors, like p21, which restricts proliferation
and the size of the crypt compartment could prevent tumor
progression.18,19,21,22,34,35,50 Beyond these canonical homeostatic mechanisms that are essential in organizing the cryptsurface axis, and are disrupted in tumorigenesis, GUCY2C
might directly oppose APC-β-catenin signaling. The guanylin-GUCY2C-cGMP axis regulates intracellular concentrations of β-catenin, and its downstream transcriptional
targets like c-Myc and axin, in intestinal cells.18,19,34,50 This
regulation may involve suppression of β-catenin mRNA
transcription through a mechanism mediated by cGMPdependent protein kinase.51,52 In that context, it is tempting
to speculate that there may be a reciprocal negative feedback
loop between guanylin-GUCY2C and APC-β-catenin signaling systems organizing the crypt-surface axis.18,19,34,51,52 In
this paradigm, Wnt signaling at the base of the crypt suppresses the guanylin-GUCY2C-cGMP axis, favoring regeneration and proliferation. Conversely, guanylin-GUCY2C
signaling at the surface suppresses APC-β-catenin signaling,
favoring
cellular
differentiation
and
maturation.
Tumorigenesis co-opts this regulatory mechanism, and
mutant Wnt signaling suppresses guanylin expression
because cGMP signaling blocks nuclear β-catenin accumulation required for transformation.
The present observations demonstrate that guanylin
expression is transcriptionally repressed by APC-β-cateninTCF signaling in intestinal epithelial cells. In turn, suppression of guanylin expression, which silences the GUCY2C
signaling axis, appears to contribute to APC-β-catenindriven colorectal tumorigenesis. These studies reveal for the
first time a novel molecular step leading from mutations in
APC that constitutively activate Wnt signaling to transformation of intestinal epithelial cells. Surprisingly, silencing of the
GUCY2C tumor suppressor occurs through a previously
unanticipated mechanism of hormone loss, rather than
through genetic inactivation of the receptor by a mutational
event. In turn, loss of guanylin hormone, but retention of the
GUCY2C receptor, expands the prevailing paradigm for colorectal tumorigenesis from an irreversible oncogenomic disease of mutational APC inactivation to a reversible functional
disease of hormone insufficiency. Indeed, guanylin loss
induced by mutant APC-β-catenin signaling creates a unique
disease-specific vulnerability that can be leveraged to eliminate tumor initiation by oral GUCY2C hormone
replacement.31 The potential for immediate translation of
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these observations is underscored by the availability of the
oral GUCY2C agonists linaclotide (Linzess™) and plecanatide
(Trulance™) to treat chronic constipation syndromes.13,17,31

Materials and methods
Human samples
The study was approved by the local Institutional Review
Board (control #14D.376). For these studies, specimens were
provided in a de-identified fashion by the Department of
Pathology at Thomas Jefferson University Hospital and
Cooperative Human Tissue Network (CHTN: https://www.
chtneast.org). All tumors underwent routine clinical profiling
in the Department of Pathology to ensure that they originated
through the conventional pathway (Apc-β-catenin) by
demonstrating that they were wild type with respect to
BRAF (eliminating tumors arising from the serrated pathway)
and mismatch repair proficient, with intact MLH1, MSH2,
PMS2, and MSH6 (eliminating tumors arising from the
microsattelite instability pathway).53
Animal models
All animal protocols were approved by the Thomas Jefferson
University Institutional Animal Care and Use Committee.
ApcCKO mice contain a conditional knockout allele of APC
with loxP sites flanking exon 14, producing a truncated APC
protein in the context of Cre-mediated recombination (NCI
Mouse Repository, #01XAA).54 ApcCKO mice were crossed
with our previously characterized vil-Cre-ERT2 mice to
induce biallelic APC inactivation in intestinal epithelial cells
(vil-Cre-ERT2-ApcCKO/CKO).20 Mice were bred onto the
ROSAmT/mG background, a fluorescent Cre-reporter model
that expresses membrane-targeted green fluorescent protein
in recombined cells.55 Breeding strategies used to generate
the appropriate models have been described.20 Conditional
mouse models were induced with intraperitoneal administration of tamoxifen.20 All mice were genotyped by sequencing
DNA from tail-clips.
Cell culture reagents
McCoy’s 5A and Dulbecco’s Modified Eagle Medium-F12
(DMEM-F12) were obtained from Thermo Fisher Scientific
(Waltham, MA). Hygromycin B, zeocin, blasticidin hydrochloride, and doxycycline hydrochloride also were from
Thermo Fisher Scientific. HyClone fetal bovine serum was
obtained from GE Healthcare Life Sciences (Pittsburgh, PA).
Zinc chloride was obtained from Sigma (St. Louis, MO).
Cells
LS174T and DLD1 cells containing either the Tet-inducible
siRNA to β-catenin or dominant-negative TCF4 (DNTCF4)
were obtained from Dr. H. Clevers in November 2013.10,44
LS174T and DLD1 cells were cultured in DMEM-F12 containing 10% FBS, Zeocin (500 µg/mL), and blasticidin (10 µg/mL).
Conditional cell lines were induced with 1 µg/mL doxycycline.

HT29 cells containing the zinc-inducible APC construct were
received from Dr. B. Vogelstein in September 2013.43 HT29
cells were cultured in McCoy’s 5A containing 10% FBS and
Hygromycin (600 µg/mL), and were induced with 300 µM
zinc chloride. Conditional cell lines were authenticated at each
use by testing their genetic inducibility. Cell lines were confirmed to be free of mycoplasma semiannually.

Immunofluorescence
Tissues were fixed in 4% paraformaldehyde, processed and
embedded in paraffin. Antigens were retrieved (Dako target
retrieval buffer pH 9.0 or sodium citrate buffer pH 6.0
depending on application) and stained. Antibody to βcatenin was from Santa Cruz Biotechnology (Dallas, TX),
Anti-PCNA (#29, 1:1000) was from Abcam (Cambridge,
MA), and anti-GUCA2A for human guanylin (#HPA018215,
1:500) was from Sigma. Guanylin antisera (#2538, 1:100) used
for mouse tissue staining was a gift from Dr. M. Goy.56
Monoclonal antibodies to GUCY2C (1:2,000) were previously
validated.34 Background autofluorescence was reduced with
sudan black (0.5% solution in 70% ethanol). Secondary antibodies were from Thermo Fisher Scientific. GUCY2C and
GUCA2A
were
detected
using
tyramide
signal
amplification.33 Fluorescence images were captured with an
EVOS FL auto cell imaging system (Thermo Fischer
Scientific). To quantify GUCA2A and GUCY2C protein
expression, a single in-focus plane was acquired. Using
ImageJ software, quantification in defined regions of interest
(ROIs) was performed by calculating corrected total cell fluorescence
(CTCF),
using
the
following
equation:
[CTCF = integrated density – (area of selected cell X mean
fluorescence of background readings)]. CTCF for each tissue
section was calculated relative to control ROI.

Immunoblots
Protein was extracted from intestinal mucosa dissected from
mouse intestine (20–50 µg protein per lane) or total lysates
from cells (106/well, 6-well plates) from in vitro experiments.
Tissue or cell lysates were extracted in T-Per or M-Per (Thermo
Fisher Scientific), respectively, supplemented with protease and
phosphatase inhibitors (Roche, St. Louis, MO). Protein was
quantified by immunoblot analysis employing antibodies to:
GFP (cat. #13970, 1:1000), Axin2 (cat. #32197, 1:1000), c-Myc
(cat. #32072, 1:1000) from Abcam; GAPDH (cat. #2118, 1:5000),
β-catenin (cat. #8480, 1:1000), human APC (cat. #2504, 1:1000),
TCF4 (cat. #2569, 1:1000), β-Actin (cat. #4967, 1:3000), phosphorylated VASP-ser239 (cat. #3114, 1:1000) from Cell Signaling
Technology (Danvers, MA); mouse APC (cat. #896, 1:1000)
from Santa Cruz Biotechnology (Dallas, TX); GUCA2A (cat. #
HPA018215, 1:100) from Sigma or guanylin antisera (#2538,
1:100);56 and GUCY2C (1:500).34 Immunoblot images were
captured on the BioRad ChemiDoc MP imaging station and
bands were quantified by densitometry normalized to that of
GAPDH or β-actin using ImageJ. Average relative intensity
reflects at least two independent experiments each with at least
three biological replicates.
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Messenger RNA analysis

Disclosure of Potential Conflicts of Interest

Tissue samples were flash frozen in liquid nitrogen and stored
at −80°C until use; cell samples were lysed directly and used
fresh. RNA was extracted and purified using the RNeasy kit
(Qiagen, Germantown, MD). Following isolation, RNA concentration and purity were measured using the Nanodrop
1000 (Thermo Fisher Scientific) and two-step quantitative
(q)RT-PCR used to interrogate gene expression.
Complementary DNA was produced using the Taqman RTPCR kit (Life Technologies, Carlsbad, CA) according to the
manufacturer’s specifications and then quantified by PCR
(Applied Biosystems, Foster City, CA) using Taqman primer
probes (Life Technologies).

SAW is a member of the Board and Chair of the Scientific Advisory
Board of, and AES is a consultant for, Targeted Diagnostics &
Therapeutics, Inc. which provided research funding that, in part, supported this work and has a license to commercialize inventions related to
this work.

New RNA synthesis
Newly synthesized RNA was prepared using ethynyl-uridine
(EU) “click” chemistry, with the Click-iT nascent RNA capture kit (cat. #C10365, Thermo Fisher Scientific). Briefly,
inducible cancer cell lines were cultured for two to three
days in the presence of inducing agent (doxycycline or zinc),
followed by EU (500 nM) for three hours, which is incorporated into newly synthesized RNA. Total cell RNA was
extracted as above using the Qiagen RNeasy kit and stored
at −80°C until further use. EU-RNA was isolated from total
RNA by a copper-catalyzed “click” reaction between the reactive alkyne moiety and biotin azide, followed by capture with
magnetic streptavidin-coated beads. Captured EU-RNA was
immediately reverse transcribed to produce complementary
DNA and quantified by PCR, as above.

Statistical analyses
Statistical significance was determined by either one-way
ANOVA or two-tailed Student’s t test, where appropriate,
for analyses of immunoblot and immunoflouresence intensity,
mRNA fold change determinations, and biochemical assays.
For animal studies, minimum cohort sizes were computed
using a power of 80% and a significance level of 0.05 (2-tailed
test) employing a priori predictions of effect size and variance
established by preliminary studies or literature review.
Operators were blinded to sample identities for analyses.
Comparisons between two groups at single time points were
analyzed by Student’s t test, or by the Mann-Whitney test for
measures not satisfying normality assumptions. All statistical
tests were calculated using GraphPad Prism (La Jolla, CA).
Analyses represent mean ± SEM of n = 3, unless otherwise
indicated, and * p < .05, ** p < .01, *** p < .001, ****,
p < .0001.
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